Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis

Journal of Investigative Dermatology

Volumn 133, Issue 8, 2013, Pages 1979-1989

  Hinchcliff, Monique ^a   Huang, Chiang Ching ^a   Wood, Tammara A ^b   Matthew Mahoney, J ^b   Martyanov, Viktor ^b   Bhattacharyya, Swati ^a   Tamaki, Zenshiro ^a   Lee, Jungwha ^a   Carns, Mary ^a   Podlusky, Sofia ^a   Sirajuddin, Arlene ^a   Shah, Sanjiv J ^a   Chang, Rowland W ^a   Lafyatis, Robert ^c   Varga, John ^a   Whitfield, Michael L ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; GRANZYME B; IMATINIB; INTERLEUKIN 6; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOFLUORESCENCE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PURINE METABOLISM; RAYNAUD PHENOMENON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

EID: 84880326024     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.130     Document Type: Article

References (31)

1. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581-90
2. Bhattacharyya S, Sargent JL, Du P et al. (2011) Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS One 6:e23082
3. Chung L, Fiorentino DF, Benbarak MJ et al. (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60:584-91
4. Dennis G Jr, Sherman BT, Hosack DA et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3
5. Derk CT, Grace E, Shenin M et al. (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595-9
6. Farina G, Lafyatis D, Lemaire R et al. (2010) A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 62:580-8
7. Farina G, Lemaire R, Korn JH et al. (2006) Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 25:213-22 (Pubitemid 43729069)
8. Farina G, Lemaire R, Pancari P et al. (2009) Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 68:435-41
9. Greenblatt MB, Sargent JL, Farina G et al. (2012) Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subsetspecific targets. Am J Pathol 180:1080-94
10. Herrick AL, Lunt M, Whidby N et al. (2010) Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 37:116-24
11. Hinchcliff M, Varga J (2011) Managing Systemic Sclerosis and its Complications. J Musculoskeletal Med 28:380
12. Kazerooni EA, Martinez FJ, Flint A et al. (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 169:977-83 (Pubitemid 27406888)
13. Khanna D, Furst DE, Hays RD et al. (2006) Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 65:1325-9 (Pubitemid 44620441)
14. Lafyatis R, Kissin E, York M et al. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578-83
15. Le EN, Wigley FM, Shah AA et al. (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104-7
16. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-5 (Pubitemid 18073738)
17. Liu Y, Hayes D, Nobel A et al. (2008) Statistical significance of clustering for high-dimension, low-sample size data. J Am Stat Assoc 103:1281-93
18. Mendoza FA, Nagle SJ, Lee JB et al. (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241-7
19. Merkel PA, Silliman NP, Clements PJ et al. (2012) Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 64:3420-9
20. Milano A, Pendergrass SA, Sargent JL et al. (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3:e2696
21. Pendergrass SA, Lemaire R, Francis IP et al. (2012) Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132:1363-73
22. Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17:681-4
23. Reimand J, Arak T, Vilo J (2011) g:Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 39:W307-15
24. Roos N, Poulalhon N, Farge D et al. (2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321:583-9 (Pubitemid 46624497)
25. Sargent JL, Milano A, Bhattacharyya S et al. (2010) A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694-705
26. Sargent JL, Whitfield ML (2011) Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Exp Rev Clin Immunol 7:463-73
27. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-5 (Pubitemid 37033947)
28. Strollo D, Goldin J (2010) Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep 12:156-61
29. Vanthuyne M, Blockmans D, Westhovens R et al. (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:287-92 (Pubitemid 46851433)
30. Verrecchia F, Laboureau J, Verola O et al. (2007) Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 46:833-41 (Pubitemid 47061718)
31. Whitfield ML, Sherlock G, Saldanha AJ et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000 (Pubitemid 34651487)